lyell.com valid

Lyell

This is an example page. It’s different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most

For agents: Lyell is a cell therapy company with a CAR-T pipeline; the site offers pipeline details, a science resource library of clinical publications and careers.

cell therapycar-toncology pipelineclinical researchresource library

Their llms.txt

The beginning of the file, from our validated copy saved 2026-10-21T18:47:55.291Z. Cached copy · Source on lyell.com

# Lyell

> This is an example page. It’s different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most


## Pages

- [Site Map](https://lyell.com/site-map/)
- [Access Policy](https://lyell.com/access-policy/)
- [Cookie Policy](https://lyell.com/cookie-policy/)
- [Contact](https://lyell.com/contact/)
- [Job Openings](https://lyell.com/careers/job-openings/)
- [Careers](https://lyell.com/careers/)
- [Cell Therapy](https://lyell.com/cell-therapy/)
- [Pipeline](https://lyell.com/pipeline/)
- [Resource Library](https://lyell.com/science/resource-library/)
- [Science](https://lyell.com/science/)
- [Leadership](https://lyell.com/about/leadership/)
- [About](https://lyell.com/about/)
- [Privacy Policy](https://lyell.com/privacy-policy/)
- [Home Page](https://lyell.com/)


## Resources

- [Durable Clinical Responses With Rondecabtagene Autoleucel (Dual-Targeting CD19/CD20 CAR-T Cell) are Associated With Higher Proportion of Cytotoxic T Cells With Memory Potential in Infusion Products](https://lyell.com/resource/durable-clinical-responses-with-rondecabtagene-autoleucel-dual-targeting-cd19-cd20-car-t-cell-are-associated-with-higher-proportion-of-cytotoxic-t-cells-with-memory-potential-in-infusion-products/)
- [Low-Grade CRS and ICANS With Rondecabtagene Autoleucel, a Dual-Targeting CD19/CD20 CAR T-Cell Product Candidate, in Patients With Large B-Cell Lymphoma: Updated Safety Analysis](https://lyell.com/resource/low-grade-crs-and-icans-with-rondecabtagene-autoleucel/)
- [Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial](https://lyell.com/resource/chimeric-antigen-receptor-t-cells-targeting-cd19-and-gcc-in-metastatic-colorectal-cancer-a-nonrandomized-clinical-trial/)
- [Rondecabtagene Autoleucel, an Autologous, Dual-Targeting CD19/CD20 CAR T-Cell Candidate Manufactured from CD62L+ Enriched T Cells, Achieves Durable Responses in Patients with Large B-Cell Lymphoma](https://lyell.com/resource/rondecabtagene-autoleucel-an-autologous-dual-targeting-cd19-cd20-car-t-cell-candidate-manufactured-from-cd62l-enriched-t-cells-achieves-durable-responses-in-patients-with-large-b-cell-lymphoma/)
- [LYL314, a CD19/CD20 CAR T-Cell Candidate Enriched for CD62L+Stem-Like Cells, Achieves High Rates of Durable Complete Responses in R/R Large B-Cell Lymphoma](https://lyell.com/resource/lyl314-a-cd19-cd20-car-t-cell-candidate-enriched-for-cd62lstem-like-cells-achieves-high-rates-of-durable-complete-responses-in-r-r-large-b-cell-lymphoma/)
- [CD62L Enrichment Achieves Robust Expansion and Memory Phenotype Post-Infusion in Patients with LBCL Treated with Rondecabtagene Autoleucel, an Autologous, Dual-Targeting CD19/CD20 CAR T-Cell Candidate](https://lyell.com/resource/cd62l-enrichment-achieves-robust-expansion-and-memory-phenotype-post-infusion-in-patients-with-lbcl-treated-with-rondecabtagene-autoleucel-an-autologous-dual-targeting-cd19-cd20-car-t-c
…

Related sites

Other listed sites in Healthcare. See the whole category →

Machine-readable: GET /v1/resolve?q=lyell.com · GET /v1/domain/lyell.com · this page as Accept: application/json or text/markdown · MCP lookup_domain

Automatically discovered from public files. Inclusion does not imply endorsement or publisher participation.

Claim my listing on Agent Web Map for lyell.com:
1. POST https://agentwebmap.com/v1/sites/lyell.com/claims and keep claim_id and claim_secret private.
2. Publish the proof: add the line "AgentWebMap ownership: <token>" (token from step 1) to https://lyell.com/llms.txt, or use the DNS, meta-tag or well-known method the response describes.
3. POST https://agentwebmap.com/v1/sites/lyell.com/verify with {"claim_id": "...", "claim_secret": "..."}.
4. Save the api_key from the answer; it manages the listing (PATCH https://agentwebmap.com/v1/sites/lyell.com).
MCP equivalent: tools begin_ownership_claim, then verify_domain, at https://agentwebmap.com/mcp. Docs: https://agentwebmap.com/docs#verify

Corrections or removal requests: contact the directory.